The short duration of the follow-
Conditions
Interventions
Patients in the experimental group received 50 mg/kg Magnesium sulfate 50% intravenous (diluted in 100 ml normal saline). Control group received 20 cc of normal saline (infused with the same volume as
Experimental Drug,Placebo Comparator Drug
magnesium ,normal saline
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were: aged 18-45 years, the presence of regular menstrual cycle, features of pelvic endometriosis (posterior, middle and anterior compartments) and/ or adenomyosis according to the revised American Society for Reproductive Medicine (ASRM) classification and the presence of ovarian endometrioma or uterine adenomyosis at clinical and transvaginal ultrasound (TV-US), taking 2-4 cc of TOP and 2-4 mg Buprenorphine Sublingual.
Exclusion criteria
Exclusion criteria: Exclusion criteria were: Hypersensitivity to magnesium sulfate, 18>BMI>35, previous surgical treatment, hormonal therapy in the last 6 months, use of drugs affecting Neuromuscular Function, history of renal disease, hepatitis, current pregnancy, major medical illnesses, Spinal disease, neuropathy, hypomagnesemia (serum magnesium concentration 2.6 mg/dL); taking Calcium-channel blockers (CCBs), AV block degree II or III, systolic blood pressure 38 °C, history of heart disease, Liver failure, respiratory disease, renal failure, gastrointestinal bleeding, metabolic disorder, active peptic ulcer, and seizure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain 24-week Visual Analogue Scale (VAS) | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life 24-week Quality of life questionnaire | — |
Countries
iran
Contacts
Public Contactbijan pirnia
Bijan Center for Substance Abuse Treatment, tehran, iran
Outcome results
None listed